These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20373480)

  • 1. Varenicline does not increase serum BDNF levels in patients with nicotine dependence.
    Umene-Nakano W; Yoshimura R; Yoshii C; Hoshuyama T; Hayashi K; Hori H; Katsuki A; Ikenouchi-Sugita A; Nakamura J
    Hum Psychopharmacol; 2010 Apr; 25(3):276-9. PubMed ID: 20373480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in plasma brain-derived neurotrophic factor levels in smokers after smoking cessation.
    Bhang SY; Choi SW; Ahn JH
    Neurosci Lett; 2010 Jan; 468(1):7-11. PubMed ID: 19850105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.
    Foulds J
    Int J Clin Pract; 2006 May; 60(5):571-6. PubMed ID: 16700857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of metabolites of catecholamine in nicotine-dependent patients treated with varenicline.
    Umene-Nakano W; Yoshimura R; Yoshii C; Hayashi K; Ikenouchi-Sugita A; Katsuki A; Hori H; Nakamura J
    Nicotine Tob Res; 2012 Apr; 14(4):486-9. PubMed ID: 22006914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness.
    Stapleton JA; Watson L; Spirling LI; Smith R; Milbrandt A; Ratcliffe M; Sutherland G
    Addiction; 2008 Jan; 103(1):146-54. PubMed ID: 18028247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
    Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
    Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
    Lam S; Patel PN
    Cardiol Rev; 2007; 15(3):154-61. PubMed ID: 17438382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varenicline for smoking cessation.
    Tonstad S
    Expert Rev Neurother; 2007 Feb; 7(2):121-7. PubMed ID: 17286546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced affective symptoms during tobacco dependence treatment with varenicline.
    Grosshans M; Mutschler J; Hermann D; Mann K; Diehl A
    Addiction; 2009 May; 104(5):859-61. PubMed ID: 19413797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of varenicline for smoking cessation.
    Hays JT; Ebbert JO; Sood A
    Am J Med; 2008 Apr; 121(4 Suppl 1):S32-42. PubMed ID: 18342165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New drugs; varenicline].
    van Bronswijk H; Dubois EA; Zitman FG; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(45):2503-4. PubMed ID: 18062594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
    Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
    Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotine dependence and smoking cessation.
    Tan L; Tang Q; Hao W
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Nov; 34(11):1049-57. PubMed ID: 19952392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Varenicline for smoking cessation: a placebo-controlled, randomized study.
    Wang C; Xiao D; Chan KP; Pothirat C; Garza D; Davies S
    Respirology; 2009 Apr; 14(3):384-92. PubMed ID: 19192221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Fagerström Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data.
    Fagerström K; Russ C; Yu CR; Yunis C; Foulds J
    Nicotine Tob Res; 2012 Dec; 14(12):1467-73. PubMed ID: 22467778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers.
    Loughead J; Ray R; Wileyto EP; Ruparel K; Sanborn P; Siegel S; Gur RC; Lerman C
    Biol Psychiatry; 2010 Apr; 67(8):715-21. PubMed ID: 20207347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study.
    Boudrez H; Gratziou C; Messig M; Metcalfe M
    Curr Med Res Opin; 2011 Apr; 27(4):769-75. PubMed ID: 21294601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased plasma brain-derived neurotrophic factor levels in chronic smokers following unaided smoking cessation.
    Kim TS; Kim DJ; Lee H; Kim YK
    Neurosci Lett; 2007 Aug; 423(1):53-7. PubMed ID: 17662528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New tobacco dependence drug: Varenicline, partial agonist of alpha4beta2 acetylcholine-nicotine receptors].
    Králíková E
    Cas Lek Cesk; 2006; 145(11):832-4. PubMed ID: 17168413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.